Background: Graft-versus-host disease is the most common complication after allogeneic hematopoietic stem cell transplantation. While ocular graft-versus-host disease typically manifests as dry eye syndrome and anterior segment involvement, posterior segment complications are rare. Previously reported posterior segment complications in graft-versus-host disease have been limited to acute presentations with significant functional visual impairment. Methods: A 41-year-old man developed progressive retinal nerve fiber layer and ganglion cell layer loss four years after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. The patient had established chronic graft-versus-host disease with cutaneous involvement and ocular surface disease. Results: Despite preserved visual acuity and visual fields, and only subtle functional involvement on visual evoked potentials, optical coherence tomography revealed significant reduction in retinal nerve fiber layer thickness and ganglion cell layer. Magnetic resonance imaging showed no optic nerve or brain abnormalities. Conclusions: This case describes an uncommon presentation of chronic, subclinical posterior segment involvement in chronic GVHD and suggests that optical coherence tomography may detect progressive structural retinal changes in the absence of clinically evident visual impairment, supporting its potential role in longitudinal monitoring.

Purpose: To describe a simple, reproducible marking technique to confirm correct epithelial orientation of human amniotic membrane (hAM) during subretinal implantation in complex vitreoretinal surgery for massive subretinal hemorrhage. Methods: A single-surgeon case report of a patient with massive subretinal hemorrhage managed by 23-gauge pars plana vitrectomy, retinal turnover, and subretinal hAM implantation. Prior to intraocular insertion, an “F” letter mark was applied to the epithelial surface of the graft using gentian violet dye, enabling unambiguous identification of membrane orientation throughout folding and intraocular delivery. Results: The gentian violet “F” mark remained clearly visible at each surgical step — forceps insertion and subretinal placement — enabling immediate confirmation of graft orientation and correct apposition of the stromal surface against the retinal pigment epithelium. No intraoperative complications related to the dye were observed. Postoperative optical coherence tomography (OCT) confirmed anatomically correct graft positioning, stable retinal reattachment, and progressive improvement in best-corrected visual acuity (BCVA). Conclusion: Gentian violet “F” marking of the hAM epithelial surface is a straightforward, safe, and reproducible adjunct for orientation verification in complex vitreoretinal surgery, where tissue transparency and repeated intraocular manipulation pose a significant risk of incorrect graft placement.

Purpose: To evaluate the anatomical and functional outcomes of an epiretinal cryopreserved human amniotic membrane (hAM) overlay technique for the management of recurrent retinal detachment (RD) associated with peripapillary breaks in highly myopic eyes. Methods: Retrospective interventional case series including five eyes with recurrent RD (mean axial length 30.70 ± 2.03 mm). Two eyes presented with recurrence under silicone oil (SO) tamponade, and three after prior SO removal. All eyes underwent 25-gauge pars plana vitrectomy with SO removal when present. A customized 8–9 mm hAM patch was positioned epiretinally and unrolled bimanually under perfluorocarbon liquid (PFCL). Final tamponade was achieved with SO 1000 cSt, followed by scheduled SO removal. Results: Complete retinal reattachment was achieved in all cases (100%) after a single procedure and remained stable throughout follow-up. Mean best-corrected visual acuity (BCVA) improved from 1.00 ± 0.60 to 0.68 ± 0.58 logMAR at 2 months after SO removal (p = 0.068). Optical coherence tomography demonstrated stable integration of the hAM as a hyperreflective layer over the peripapillary defects. No cases of graft dislocation, proliferative vitreoretinopathy, or significant inflammatory complications were observed. Conclusions: The epiretinal hAM overlay technique appears to be a safe and effective approach for sealing complex peripapillary breaks in highly myopic eyes with chorioretinal atrophy. By providing both mechanical support and a biological scaffold for tissue repair, this technique may represent a valuable surgical option in cases where conventional retinopexy is not feasible or has failed.

Purpose: To evaluate visual and anatomical outcomes after switching to aflibercept 8 mg in eyes with neovascular age-related macular degeneration (nAMD), and to assess outcomes according to the clinical indication for switching. Methods: Multicentre retrospective observational study including 300 eyes with nAMD previously treated with anti-vascular endothelial growth factor therapy and switched to aflibercept 8 mg for non-response (n:74, 24.7%), suboptimal response (n:159, 53.0%), or durability-driven reasons (n:67, 22.3%). Longitudinal data from the 6 months preceding the switch and post-switch visits at 3 and 6 months were analyzed. The primary outcome was change in best-corrected visual acuity (BCVA, ETDRS letters) from the switch visit to the 3-month post-switch visit. Secondary outcomes included changes in central subfield thickness (CST) and retinal fluid status. Results: During the pre-switch period, mean BCVA declined by − 1.9 ± 8.2 letters and CST increased. At 3 months after switching, BCVA improved by + 2.0 ± 9.2 letters (95% CI, + 0.8 to + 3.2; p < 0.01), with greater gains in eyes switched for non-response (+ 2.8 ± 12.6 letters). Mean CST decreased by − 45.3 ± 79.8 µm (95% CI, − 55.4 to − 35.2; p < 0.001), with corresponding reductions in retinal fluid. Anatomical improvements were more pronounced in eyes switched for non-response, whereas more modest but consistent changes were observed in suboptimal and durability-driven groups. Visual and anatomical outcomes were maintained at 6 months. Conclusions: In previously treated nAMD eyes, switching to aflibercept 8 mg was associated with reversal of pre-switch anatomical worsening, reduction in retinal fluid, and modest visual gains. Greater responses were observed in eyes with inadequate pre-switch disease control, supporting its role as a treatment escalation strategy in clinical practice.